Neuroprotective actions of selegiline

Journal of Neuroscience Research

Volumn 67, Issue 3, 2002, Pages 285-289

  Ebadi, M ^a   Sharma, S ^a   Shavali, S ^a   El Refaey, H ^a  

^a UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMINO ACID DECARBOXYLASE; AMPHETAMINE; DOPAMINE RECEPTOR; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROTOXIN; PLACEBO; SELEGILINE;

APOPTOSIS; AUTOOXIDATION; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; ENZYME REGULATION; HUMAN; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROTONINERGIC NERVE; SHORT SURVEY;

ANIMALS; ANTIPARKINSON AGENTS; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSON DISEASE; SELEGILINE; TREATMENT OUTCOME;

EID: 0036469890     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10148     Document Type: Short Survey

References (36)

1. Rescue of axotomized immature rat-facial motoneurons by R(-)-deprenyl: Stereospecificity and independence from monoamine oxidase inhibition
2. Comparative study of selegiline plus L-DOPA-carbidopa versus L-DOPA-carbidopa alone in the treatment of Parkinson's disease
3. The effects of oxidative stress on in vivo brain GSH turnover in young and mature mice
4. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
5. Therapeutic potential of selegiline in Parkinson's disease and other neurological disorders
6. Glutathione and metallothionein in oxidative stress of Parkinson's disease
7. Oxidative stress and antioxidant therapy in Parkinson's disease
8. Neurotrophins and their receptors in nerve injury and repair
9. Metallothionein, neurotropins, and selegiline in providing neuroprotection in Parkinson's disease
10. Basic fibroblast growth factor in the hypoglossal system: Specific retrograde transport, trophic and lesion-related responses
11. Neuroprotection: A reachable therapeutic goal?
12. Some observations upon a new inhibitor of monoamine oxidase to brain tissue
13. (-)Deprenyl (selegiline): Past, present, and future
14. Selegiline and Parkinson's disease: It's déjà vu - Again
15. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
16. Neuroprotective and neuronal rescue effects of selegiline
17. Some new aspects of the effect of (-)-deprenyl in Parkinson's disease: A retrospective study
18. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide
19. +, and β-carbolinium: A microdialysis study in rats
20. Potential of neurotrophic factors in therapy of Parkinson's disease
21. New directions in the drug treatment of Parkinson's disease
22. Selegiline as initial treatment in de novo parkinsonian patients
23. Selegiline as the primary treatment of Parkinson's disease: A long-term double-blind study
24. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro
25. Future of neuroprotection in Parkinson's disease
26. MPTP neurotoxins inducing cell death and a substrate for B form of enzyme monamine oxidase
27. Selegiline and mortality in Parkinson's disease
28. Mortality in DATATOP: A multicenter trial in early Parkinson's disease
29. R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium
30. Deprenyl, excess mortality, and epidemiological traps
31. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic
32. Brain-derived neurotrophic factor prevents the death of motoneuron in newborn rats after nerve section
33. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease
34. Antiapoptotic and apoptotic action of (-)-deprenyl and its metabolites
35. Does selegiline delay progression of Parkinson's disease? A critical reevaluation of the DATATOP study
36. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death